Sollte der Newsletter nicht richtig angezeigt werden, besuchen Sie bitte unsere Website:   >>>


Newsletter EPO GmbH: Montag, 5. November 2018

EPO at 30th EORTC-NCI-AACR Conference

- Molecular Targets Cancer Therapeutics -
13. – 16. Nov 2018 Dublin


Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer

PDX Expert: Dr. Diana Behrens

Dr. Behrens provided information about the development of new models for pancreatic cancer and how to evaluate combination therapies in preclinical models.

The described PDX panel clearly reflects clinical pancreatic cancer histology, growth and inherent and acquired treatment resistance as well as recurrent disease.

Poster 1


Preclinal models of patient-derived xenografts on humanized mice for translational immuno-oncology research

Tumor-Immunology Expert:
Dr. Annika Wulf-Goldenberg

Dr. Wulf-Goldenberg is one of our most experienced experts in immune oncology research.

Learn more about our capability to engraft patient-derived tumor xenografts (PDX) on humanized mice and how to evaluate the combination of radiotherapy with immune checkpoint inhibition, in syngeneic cancer models.

Poster 1

Poster 2


. find  out further 500 well characterized PDX models: www.epo-berlin.com

(search online for molecular and pharmacological characteristics)   

We hope to have the pleasure of seeing you at the ENA meeting and providing you with
any information you need!

If you are interested to know more about EPO’s expertise,
please visit us

http://www.epo-berlin.com/

We are looking forward meeting you there.

      Connect with us: EPOatENA@epo-berlin.com to schedule a meeting with our experts.

Impress:

EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH
Robert-Rössle-Straße 10, Haus 82
13125 Berlin Germany

Amtsgericht Charlottenburg,Sitz Berlin, HRB 61814


Wenn Sie diesen Newsletter nicht mehr erhalten möchten, dann klicken Sie bitte auf abbestellen. 

Copyright:EPO GmbH© 2018 

unsubscribe